Misleading promotion lands NJ drugmaker a letter from FDA
Edenbridge Pharmaceuticals received this year's first untitled letter from the FDA's drug promotion office over misleading claims in an advertisement for the company's multiple myeloma drug Hemady. The FDA said in ...
Edenbridge Pharmaceuticals received this year's first untitled letter from the FDA's drug promotion office over misleading claims in an advertisement for the company's multiple myeloma drug Hemady.
The FDA said in ...
